TGTX vs STAG Comparison

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Stag Industrial Inc is a REIT focused on the acquisition, ownership, development, and operation of industrial properties throughout the United States. Its platform is designed to (i) identify properties for acquisition that offer attractive returns across CBRE-EA Tier 1 industrial real estate markets, industries, and tenants, (ii) provide growth through the ownership of high-quality assets, property management and pursuit of acquisitions in an attractive opportunity set, and (iii) capitalize its business appropriately given the characteristics of its assets. The majority of its portfolio is single-tenant industrial properties throughout the United States. The company derives the majority of its rental revenue from its facilities located in Midwestern and Eastern U.S. cities.